Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)
Initiated February 2020, recruiting
ClinicalTrials.gov Identifier: NCT04069312
About the study
The COPD Foundation is partnering with top pulmonary doctors and researchers at more than 30 institutions across the country to conduct the RELIANCE study. RELIANCE is a clinical trial that compares two medicines currently used for COPD, azithromycin and roflumilast. Research shows that both drugs work to help control COPD attacks and hospitalizations. What we don’t know is which drug works better and for whom.
As a partner on RELIANCE, the COPD Foundation will engage the COPD Patient Powered Research Network (PPRN), lead patient and community engagement sessions, and represent the patient perspective throughout all aspects of the study.
Results from clinical trials and clinical guidelines indicate that long-term use of either roflumilast or azithromycin significantly reduces the risk of COPD exacerbations. No studies to date have directly compared long-term roflumilast to azithromycin in patients with COPD, so it is unclear how well they work when compared to each other. The RELIANCE study aims to compare roflumilast and azithromycin head-to-head to determine which therapy is best for the prevention of COPD exacerbations. The RELIANCE project was funded by the Patient Center Outcomes Research Institute. PCORI #PCS-1504-30430
For more information for patients, caregivers and clinicians click below: